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Abstract
Background: A hallmark of cancer cells is hypermethylation of CpG islands (CGIs), which probably arises from upregulation
of one or more DNA methyltransferases. The purpose of this study was to identify the targets of DNMT3B, an essential DNA
methyltransferase in mammals, in colon cancer.
Methodology/Principal Findings: Chromatin immunoprecipitation with DNMT3B specific antibody followed by CGI
microarray identified genes with or without CGIs, repeat elements and genomic contigs in RKO cells. ChIP-Chop analysis
showed that the majority of the target genes including P16, DCC, DISC1, SLIT1, CAVEOLIN1, GNA11, TBX5, TBX18, HOXB13 and
some histone variants, that harbor CGI in their promoters, were methylated in multiple colon cancer cell lines but not in
normal colon epithelial cells. Further, these genes were reactivated in RKO cells after treatment with 5-aza-29-deoxycytidine,
a DNA hypomethylating agent. COBRA showed that the CGIs encompassing the promoter and/or coding region of DCC,
TBX5, TBX18, SLIT1 were methylated in primary colorectal tumors but not in matching normal colon tissues whereas GNA11
was methylated in both. MassARRAY analysis demonstrated that the CGI located ,4.5 kb upstream of HOXB13 +1 site was
tumor-specifically hypermethylated in primary colorectal cancers and cancer cell lines. HOXB13 upstream CGI was partially
hypomethylated in DNMT1
2/2 HCT cells but was almost methylation free in cells lacking both DNMT1 and DNMT3B.
Analysis of tumor suppressor properties of two aberrantly methylated transcription factors, HOXB13 and TBX18, revealed
that both inhibited growth and clonogenic survival of colon cancer cells in vitro, but only HOXB13 abolished tumor growth
in nude mice.
Conclusions/Significance: This is the first report that identifies several important tumor suppressors and transcription
factors as direct DNMT3B targets in colon cancer and as potential biomarkers for this cancer. Further, this study shows that
methylation at an upstream CGI of HOXB13 is unique to colon cancer.
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Introduction
Symmetrical methylation of DNA at position 5 of cytosine
within a CpG dinucleotide is a major epigenetic modification
(,5% of the total cytosine in the mammalian genome) although a
small amount of 5-hydroxymethylcytosine (5hmC) generated from
5-meC by a methylcytosine dioxygenase has recently been
detected in certain cell types [1–3]. Very recently it has been
shown that cytosine methylation at nonCpG sites, although rare, is
involved in gene silencing in mammals [4]. DNA methylation is
essential for mammalian development. DNA hypermethylation
suppresses spurious promoters located within the repeat elements
and proviruses in mammalian genome whereas hypomethylation
induces genomic instability [5,6]. DNA methylation is also
involved in the regulation of genomic imprinting, inactivation of
the silent X chromosome in females and expression of certain
tissue specific genes [1,6]. In humans, alterations in genomic
methylation patterns are linked to imprinting disorders and other
human diseases including cancer [7–9].
Although CpG is usually underrepresented in much of the
genome, short (500–2000 bp long) CpG regions, designated CpG
islands (CGI), are predominantly located in the proximal promoter
regions of almost 50% of the mammalian genes. These regions are
usually methylation free in normal cells with the exception of
imprinted alleles and genes on the inactive X chromosome.
Recent high throughput genome wide DNA methylation analysis
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tissue-specifically methylated [5]. Furthermore, methylation also
occurs in the coding regions of active genes and reversible DNA
methylation can regulate gene expression in response to stimuli
such as estrogen treatment and membrane depolarization [6].
DNA methylation in mammalian cells is established and
maintained by DNA (cytosine-5) methyltransferases (DNMTs).
Methylation is initiated by highly homologous DNMT3A and
DNMT3B that prefer unmethylated DNA as the substrate [1,10].
DNA methylation is heritably propagated by DNMT1 that prefers
hemimethylated DNA as substrate. All three DNMTs are essential
for development in mammals [11,12]. Among these three
enzymes, DNMT3B is directly linked to different diseases. For
example, mutation of the DNMT3B gene causes immunodefi-
ciency, centromeric instability and facial anomalies (ICF) syn-
drome, a rare human disorder due to alteration in the methylation
of minor satellite repeats [13] and genes regulating immune
function and neuronal development [14]. Thus, DNMT3B
deficiency in these patients cannot be compensated by other
DNMTs. Studies in mutant mice have shown that DNMT3A and
DNMT3B methylate distinct as well as overlapping regions of the
genome [12]. For example, DNMT3A2 catalyzes methylation of
imprinted genes in germ cells whereas tandem repeat elements are
methylated by both DNMT3A and DNMT3B [2]. DNMT3B has
also been linked to type 2 diabetes by regulating mitochondrial
DNA copy numbers through fatty acid-induced non-CpG
methylation of PGC-1a [4]. Emerging studies have shown that a
variety of cofactors specifically target DNMTs to distinct
chromosomal regions in vivo [15], as these enzymes demonstrate
specificity only towards CpG base pairs in vitro [2]. Gene silencing
by DNMTs occurs predominantly by recruitment of repressors
that include methyl CpG binding proteins (MBDs) and co-
repressors such as histone deacetylases (HDAC) and histone
methyltransferases (HMT), resulting in distortion of local chro-
matin structure [3,9,16].
Hypermethylation of CpG islands (CGIs) is a common
epigenetic event in almost all malignancies [7,9]. Upregulation
of DNMT3B is also a characteristic of many cancer cells [17]. For
example, in sporadic breast carcinoma, 30% of the patients
showed increased expression of DNMT3B compared to minimal
increase (3–5%) in DNMT1 and DNMT3A [18]. Significantly
higher expression of DNMT3B was observed in acute myeloid
leukemia compared to normal myeloid cells [19]. DNMT3B
overexpression was associated with high tumor grade and CIMP
(CpG island methylator phenotype) in colon cancer [17].
Furthermore, depletion of DNMT3B, but not DNMT3A, induced
apoptosis specifically in human cancer cells [20]. It has also been
reported that upregulation of DNMT3B is more dramatic and
more frequent than DNMT1 and DNMT3A in cancers including
bladder and colon [21]. Studies in a mouse model have shown that
the overexpression of Dnmt3b but not Dnmt3a promoted colon
tumorigenesis in Apc
Min/+ mice [22]. These observations suggest
that DNMT3B may play a causal role in tumorigenesis.
Different groups have identified methylation targets using
different techniques [14,22], in the present study we have
identified direct DNMT3B target genes in colon cancer cells by
performing chromatin immunoprecipitation followed by CpG
island microarray analysis (ChIP-on-chip). Many DNMT3B
targets are embedded in CpG islands and some are known tumor
suppressors. We also report the methylation status of some of these
genes with potential growth suppressor properties in primary
colorectal tumors and colon cancer cell lines. Further, we
examined tumor suppressive characteristics of two important
transcription factors, HOXB13 and TBX18, in colon cancer cells.
Methods
Mice
Nude mice were purchased from Jackson laboratory. All mice
were housed, handled, and euthanized in accordance with federal
and institutional guidelines under the supervision of the Ohio State
University Institutional Animal Care and Use Committee. All
animals used in this study were handled in strict accordance with
good animal practice as defined by the relevant national and/or
local animal welfare bodies.
Cell culture, treatment with 5-aza-29-deoxy-cytidine
(decitabine) and isolation of DNA
Human colon cancer cell lines (RKO, HCT116, SW480, SW837,
Colo205, CaCo2 and DLD1b) and normal colon cell line (CCD841)
were obtained from ATCC and grown in media as suggested by
ATCC. RKO and HCT116 cells were treated with decitabine (0.1
to 5 mM) for 24–120 hours. The wild type, DNMT1
2/2,
DNMT3B
2/2 and DKO (DNMT12/2 DNMT3B
2/2) cells (a
generous gift from Bert Vogelstein) were cultured as described [23].
Western blot analysis
Affinity purified antibodies against DNMT3A and DNMT3B
were used for western blot analysis as described [24,25]. Anti-Flag
antibody was from Sigma.
Primary Human Tumors
The tumor samples were obtained from patients at James
Cancer Hospital (The Ohio State University). Complete patho-
logic classification is available for all tumor samples studied. All
tissues used for this study were part of an institutional review
board-approved protocol at the Ohio State University College of
Medicine.
ChIP on Chip assay
Chromatin immunoprecipitation (ChIP) assay was performed as
described [26] with some modifications. ChIP was performed on
formaldehyde cross-linked chromatin (DNA fragmented to
,600 bp to 3000 bp by sonication) from 10
8 RKO cells with
antibody against DNMT3B [26,27]. The anti-DNMT3B antibod-
ies raised in our laboratory do not cross react with each other or
with DNMT1 [28]. We used affinity purified DNMT3B antibodies
to pull down DNA from formaldehyde cross-linked chromatin
prepared from RKO cells. The chromatin was cleared with pre-
immune IgG and protein A beads. The precipitated DNA was
dissolved in RIPA buffer and subjected to a second round of
immunoprecipitation with the same antibody to minimize pull
down of false positive targets. This DNA was then separated on an
agarose gel and DNA from 0.5 to 3 kb in size was purified by using
Gel Extraction kit (Qiagen), labeled with Cy5-labeled dNTP and
hybridized to a CpG island library coated on glass slides [29,30].
The same amount of input DNA and DNA precipitated with
preimmune-IgG) was used as control. We selected only those genes
for sequence analysis where the signal in ChIP DNA was $2 fold
compared to the control rabbit IgG signal. MIAME complaint
data has been submitted to Geo database (accession number
GSE18929).
Sequence analysis of clones
The construction of CpG island library has been described
earlier [29]. The clones pulled own by DNMT3B antibodies were
picked up from the CpG island library and sequenced in an
automated sequencer.
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RNA was isolated using guanidinium thiocyanate-acid phenol
method, treated with DNase 1 to remove residual DNA, if any,
and reverse transcribed using random hexamers following
standard protocol. Real time RT-PCR was done using SYBR
Green technology following published protocol [27,31]. RT-PCR
primers will be available upon request.
ChIP-CHOP analysis was performed as described [32]
Primer sequences are provided in the Table S1.
COBRA (Combined bisulfite-restriction analysis)
COBRA of genomic DNA was performed as described [33,34].
CGIs different genes were amplified with primers specific for bisulfite
converted DNA where unmethylated cytosines are converted to
uracils. Primers were designed using Methprimer software (http://
www.urogene.org/methprimer/index1.html). Primer sequences are
provided in the Table S1.
Quantitative DNA methylation analysis of HOXB13 CGI by
MassARRAY
DNA methylation analyses were carried out using the
EpiTYPER application (Sequenom, San Diego) as described
[35]. Briefly, genomic DNA was isolated, subjected to integrity
control and subjected to bisulfite treatment. Regions of interest
were amplified using primers for bisulfite treated DNA (primer
sequences available upon request), amplified DNA was transcribed
in vitro and cleaved using RNAse A. The molecular weight of the
resulting fragments indicative of the DNA methylation state was
analyzed using matrix-assisted laser desorption ionization time-of-
flight (MALDI-TOF) mass spectrometry. DNA methylation
standards (0, 20, 40, 60, 80 and 100%) were used to control for
PCR amplification bias. Equation fitting algorithms based on the
R statistical computing environment were used for data correction.
Display of methylation results as heat maps and unsupervised
clustering were performed using the Multiple Experimental
Viewer software (http://www.tm4.org/mev.html).
Cloning of HOXB13 and TBX18 cDNA and generation of
RKO and HCT116 cell lines overexpressing these proteins
cDNA derived from total RNA from normal human colon
(Clontech) was amplified with primers specific for HOXB13 and
TBX18 coding region and cloned into pcDNA-3XFlag (Sigma).
The authenticity of the cDNAs was confirmed by sequencing. The
Flag-tagged cDNAs were then cloned into pBabe-puro and
infectious retroviruses were generated in phoenix cells. Stable cell
lines (RKO, HCT116 or DLD1b) overexpressing HOXB13 or
TBX18 were generated by infecting these cells with the
recombinant retroviruses and selected with puromycin.
Clonogenic survival was performed as described [36]
Cell growth was measured by MTT assay as described [37]
Tumor growth in nude mice was performed as described
[38]
HOXB13 promoter activity assay
HOXB13 promoter regions spanning 21.2 kb to +0.2 kb and
25.2 kb to +0.2 kb with respect to transcription start site (TSS)
Figure 1. Expression of DNMT3B is higher in RKO cells. A. Western blot analysis of whole cell extracts fr o mR K Oa n dH C T( w i l dt y p ea n dm u t a n t )c e l l s
with antibodies specific for DNMTs. Affinity purified antibodies against DNMT3B were used for immunoblotting. B. Real-time RT-PCR analysis of DNMTs in RKO
cells was performed using SYBR Green method. Data are mean of triplicate assays. Single and double asterisks denote p values #0.05 and #0.01, respectively.
C. Ethidium bromide staining of DNA immunoprecipitated by DNMT3B antibody and input DNA that were used for CpG island microarray analysis.
doi:10.1371/journal.pone.0010338.g001
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ase, confirmed by sequencing, and cloned into pGL3 basic (firefly
luciferase vector). These promoter reporter plasmids along with
pRLTK (renilla luciferase vector) were transfected into RKO cells
and luciferase activity was measured using Dual luciferase assay kit
(Promega).
Results
ChIP on Chip analysis identified DNMT3B target genes in
RKO, a colon cancer cell line
Aberrant DNA methylation is prevalent in colorectal carcino-
genesis [39–41]. To identify hypermethylated genes in colon cancer
(RKO) cells we performed ChIP with anti-DNMT3B followed by
CpG island (CGI) microarray. We selected DNMT3B because its
expression is significantly higher than DNMT3A and DNMT1 in
RKO cells (Figure 1A) and it appears to play a causal role in colon
tumorigenesis [22]. The specificity of the affinity purified DNMT3B
antibody was confirmed by using extracts from DNMT3B null
HCT cells. A major (,98/96 kDa) polypeptide was detected by
this antibody in RKO cells, in the wild type and DNMT1
2/2 HCT
cells. That these polypeptides are different variants of DNMT3B
was confirmed by the inability of the antibody to detect any protein
in DNMT3B
2/2 and DKO (DNMT1
2/2 DNMT3B
2/) cells. A few
very minor polypeptides detected in cells expressing DNMT3B are
probably its isoforms because it is known that DNMT3B exhibits
different spliced variants [42]. To reduce nonspecific pull down,
ChIP was performed twice with the same antibody and the
precipitated DNA was resolved on an agarose gel to elute DNA of
smaller sizes (0.5 to 3 kb) as probe for CpG island microarray (see
Methods for detail) (Figure 1B).
Next, we sequenced only those pulled-down genes that were at
least 2 fold enriched in ChIP DNA compared to that pulled down
by control rabbit IgG. The microarray data has been submitted to
Geo database and it is MIAME complaint (accession number
GSE18929). We classified these genes into four groups, i) genes
with CpG island (CGI) but without repeat elements, ii) genes
without CGI and repeat elements, iii) repeat elements, and iv)
genomic contigs associated with repeat elements (Table 1 and
Table S2). Among the genes with CGIs, there are some known
tumor suppressors, such as P16/MTS1, DDC, PGRMC1, CAVEO-
LIN1 and some disease susceptibility genes such as DISC1
(disrupted in Schizophrenia 1) [43], TBX5 (Congenital heart
failure or Holt-Oram syndrome) [44] (Table 1). We also
identified a few novel genes such as TBX18, DGKI, SLIT1 and
GNA11 as DNMT3B targets.
To confirm the association of DNMT3B with some of its
putative target genes, we amplified their promoter regions from a
different batch of chromatin immunoprecipitated DNA. We
performed ChIP-CHOP analysis to determine methylation status
of the target DNA. For this assay, the immunoprecipated DNA
was divided into three identical aliquots for mock-digestion,
digestion with Hpa II (methylation sensitive enzyme) or Msp I
(methylation insensitive enzyme) (see Figure 2A for a schematic
diagram). The digested DNA was then used to amplify the
promoter of interest using primers that encompass one or more
Table 1. Methylted DNMT3B Target Genes in RKO cells identified by ChIP on Chip.
Accession # Gene name Gene symbol
GROUP I: Genes harboring CpG island without repeat elements
NM_018662 disrupted in schizophrenia 1 DISC1
NM_003522 histone cluster 1, H2bf HIST1H2BF
NM_001080508 T-box 18 TBX18
NM_001753 Caveolin-1 CAVEOLIN1
NM_004717 diacylglycerol kinase iota DGKI
U26727 P16INK4/MTS1 CDKN2A
NM_021951 doublesex and mab-3 related transcription factor 1 DMRT1
NM_003692 transmembrane protein with EGF-like and two follistatin-like domains 1 TMEFF1
NM_003061 Slit-1 SLIT1
NM_018362 lin-7 homolog C (C. elegans) LIN7C
AF532858 Nogo-66 receptor homolog-1 NGRH1/RTN4RL2
BC031869 M.m. C.elegans ceh-10 homeo domain containing homolog Chx10
NM_181486 T-box 5 TBX5
NM_006361 homeodomain protein HOXB13 HOXB13
NM_005215 colorectal tumor suppressor DCC
NM_002067 guanine nucleotide-binding regulatory protein, alpha-11 GNA11
NM_006667 progesterone receptor membrane component 1 PGRMC1
NM_024784.3 zinc finger and BTB domain containing 3 ZBTB3
GROUP II: Genes with no CGIs or repeat elements
AY210419 CUB and sushi multiple domains 3 CSMD3
Association of DNMT3B to the target genes and their methylation status was determined by ChIP-CHOP assay. Formaldehyde-cross-linked chromatin from RKO cells was
immunoprecipitated with anti-DNMT3B or pre-immune IgG. DNA pulled down was divided into three aliquots, which were either undigested or digested with Hpa II,
Msp I and subjected to PCR with primers specific for CGIs of different genes that harbor Hpa II/Msp I sites. PCR products were resolved by agarose gel electrophoresis.
Generation of PCR product in Hpa II digested DNA indicates methylation.
doi:10.1371/journal.pone.0010338.t001
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mock-digested DNA indicates that the gene of interest is a target of
DNMT3B whereas generation of Hpa II resistant PCR product
demonstrates that the gene is methylated. PCR products are not
obtained from Msp I digested DNA since Msp I digestion is not
sensitive to methylation. Thus, ChIP-CHOP assay not only reveals
association of a gene with a certain protein but also identifies the
methylation status of the associated promoter at Hpa II sites. The
Figure 2. ChIP-CHOP assay to demonstrate association of DNMT3A and DNMT3B with the selected target genes. A. Schematic
diagram of ChIP-CHOP assay. B. Formaldehyde-cross-linked chromatin from RKO cells was immunoprecipitated with anti-DNMT3B or pre-immune
IgG. DNAs pulled down were divided into three aliquots, which were either undigested or digested with Hpa II, Msp I and subjected to PCR with
primers specific for CGIs of different genes that harbor Hpa II/Msp I sites. PCR products were resolved by agarose gel electrophoresis. Generation of
PCR product in Hpa II digested DNA indicates methylation. U, H and M indicate PCR products obtained in mock-, Hpa II- digested and Msp I-digested
DNA, respectively. Lack of PCR product with Msp I digested DNA confirmed complete digestion. C. Activation of several DNMT3B target genes in RKO
cells after treatment with decitabine. RKO cells were treated with the drug for the indicate time periods. RNA from these cells was subjected to RT-
PCR with gene-specific primers. Three hundred ng of cDNA for the test gene and 1 ng of cDNA were used for 18S rRNA.
doi:10.1371/journal.pone.0010338.g002
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of each gene as appeared in UCSC genome browser is depicted in the accompanied schematic diagrams. Bisulfite converted genomic DNA was
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DNMT3B target genes such as P16, TBX5, TBX18, GNA11,
DMRT1, HOXB13, CAVEOLIN1, PGRMC1, DCC, DGKi, CDH26,
LIN7C, ZBTB3, DISC1 and the histone H2B variant (H2Bf) are
methylated in RKO cells. Notably, TBX-18, HOXB13, DMRT1,
DISC1, H2Bf and LIN7C CGIs are partially methylated in RKO
cells at least at the Hpa II sites (as demonstrated by increased PCR
product in mock-digested DNA than in Hpa II cleaved DNA) and
DNMT3B is associated with these CGIs irrespective of their
methylation status. In contrast, DNMT3B is predominantly
associated with methylated CGIs of P16, TBX5, DCC and
PGRMC1. None of these target genes could be amplified from
chromatin immunoprecipitated with control rabbit IgG (data
shown for only TBX5) (Fig. 2B) demonstrating that these are
specific DNMT3B targets. Lack of amplification of GAPDH
promoter, a house keeping gene, from RKO genomic DNA
indicates that GAPDH CGI is methylation free and Hpa II
digestion was complete. GAPDH was not pulled down by
DNMT3B (data not shown).
Next, we tested methylation status of a few genes in other colon
cancer cell lines (DLD1b, HCT116, SW480, CACo2, COLO205,
SW837) by digestion of their genomic DNA with Hpa II/Msp I
followed by PCR with gene specific primers. While TBX5 and
DCC are methylated in all cell lines, other genes (TBX18, DGKI,
PGRMC1, LIN7C and HOXB13) are differentially methylated
(Table S3). It is noteworthy that none of these genes are
methylated in normal colon epithelial cells CCD841.
Treatment of RKO cells with decitabine resulted in
activation of the methylated genes
To determine whether methylation of some of the DNMT3B
target genes indeed suppressed their expression in RKO cells, we
treated these cells with the commonly used DNA hypomethylating
agent, 5-aza-29-deoxycytidine. RNA isolated from untreated and
the inhibitor (1 and 2.5 mM) treated RKO cells harvested at 24, 48
or 72 hours was subjected to RT-PCR analysis with gene specific
primers. TBX18, DCC and CAVEOLIN 1 were re-expressed in
RKO cells treated with 1 and 2.5 mM decitabine as early as 24 hr
and their expression persisted up to 72 hr (Figure 2B). In
contrast, SLIT1 was induced at a very low level under these
conditions whereas HOXB13 was reactivated only after exposure
to the drug for 72 hr. On the contrary, GNA11 was expressed at
high level in RKO cells indicating that the methylation of CGI
located in intron 1 of this gene did not affect its expression.
CGIs of DNMT3B target genes are methylated in human
primary colorectal tumors
Next, we extended our study to analyze the methylation status
of a selected group of genes (DCC, TBX18, TBX5, SLIT1 and
GNA11) in several primary human colorectal tumors and matching
normal colon tissues by COBRA. The methylation status of these
genes in a few pairs is presented in Figure 3. The CGI spanning
promoter/exon 1 of DCC was methylated at Taq I site in 8 out of
10 tumors as demonstrated by almost complete digestion with Taq
I whereas it was methylated in matching normal colon tissues only
in sample #8 and #10 (Figure 3.i). Similarly, CGI of TBX18 was
methylated at the BstU I site in 6 out of 7 tumors without
significant methylation in matching normals (Figure 3.ii). TBX5
encodes 4 transcript variants that are generated by alternate
transcription initiation sites and alternative splicing. We analyzed
methylation status of CGIs spanning the promoter/exon 1 of
variants 1 and 3 (TBX5L) and variant 4 (TBX5S) (Figure 3.iii).
Interestingly, CGI of TBX5L was methylated at Taq I sites both in
normal colon tissues and tumors but methylation was more
pronounced in 3 out of 5 tumors (#1, 4 & 6) than in the matching
normals. In contrast, CGI of TBX5S was specifically methylated
in tumors in 5 out of 6 samples at the BstU I site. Thus, two CGIs
located in close proximity demonstrated differential methylation
status in the same sample at least with respect to Taq I and BstUI
sites. CGI spanning promoter/exon 1 of SLIT1 was tumor-
specifically methylated at the Taq I site in 5 out of 10 samples
analyzed (Figure 3.iv). Notably CGI located in the intron of
GNA11 was completely methylated both in normals and tumors as
demonstrated by complete digestion of the PCR product with
BstUI( Figure 3.v). Methylation at this intronic CGI did not
silence GNA11 as demonstrated by its robust expression in RKO
cells (Figure 2c). Complete bisulfite conversion was demonstrated
by digestion of the amplicons with methylation insensitive Mse Io r
Tsp509 I (data not shown). These COBRA data showed that some
of DNMT3B targets were hypermethylated in primary colorectal
tumors albeit at different levels. However, we did not observe
methylation of CGI located in the promoter as well as exon 1
region of the HOXB13 gene in primary colon cancer by COBRA
(data not shown).
CGI located 4.5 kb upstream of HOXB13 Transcription
start site (TSS) is hypermethylated in colorectal tumors
Although COBRA did not reveal methylation of CGI located in
the promoter and exon 1 region, HOXB13 gene was reactivated
after treatment with decitabine (Figure 2C). This observation
suggested that methylation of a CGI located at a different region of
the gene or specific CpGs within the promoter region might
regulate its expression in colon cancer cells or tissues. BLAT
analysis identified two CGIs in human HOXB13 gene, one in the
promoter/exon1 and the other ,4.5 kb upstream of transcription
start site (TSS) (Figure 4A). We, therefore, analyzed methylation
status of CpGs spanning the promoter and upstream CGI
(Figure 4B, and Tables S4 and S5) in primary colorectal
tumors and in cell lines by MassARRAY because in this mass
spectrometry based assay methylation status of CpGs can be
estimated quantitatively. It is evident from the HEAT map that
methylation at the upstream CGI is higher in tumors than in
normals (Figure 4C.i). Quantification of the results showed that
overall methylation density at the upstream CGIs was significantly
higher (P=0.02) in tumors compared to the normals
(Figure 4C.ii). In contrast, CGI in the promoter region was
essentially methylation free (Figure 4C.i), which correlated with
the COBRA data (data not shown). MassARRAY analysis of colon
cancer cell lines revealed hypermethylation at the upstream CGI
in HCT, CaCo2 and RKO cells whereas relatively low level
methylation was detected in RWPE and SW837 cells. Notably,
CCD841, a normal colon epithelial cell line, was essentially
unmethylated. Selective methylation of the upstream CGI but not
the one located in the immediate upstream promoter region occurs
in colon cancer cells probably due to distinct chromatin structure
that is accessible to DNMTs.
To investigate the role of the upstream CGI in HOXB13
expression we generated luciferase reporter constructs harboring
25.4 kb to +0.2 kb and 21.2 kb to +0.2 kb regions, respectively
amplified with gene specific primers followed by digestion with a methylation sensitive enzyme Taq Io rBstU I. T and N denote tumor and matching
normal, respectively. Sample numbers shown in red identify tumors with gene-specific methylation.
doi:10.1371/journal.pone.0010338.g003
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firefly luciferase activity at 36 and 48 hr post transfection in
HCT116 cells, because these cells can be transfected with high
efficiency. The luciferase activity driven by 25.4 kb promoter was
at least 2 fold higher than that contributed by 21.2 kb region
(Figure 4D). Promoterless pGL3basic showed minimal activity
(data not shown). Since HOXB13 is an estrogen responsive gene
[45], we also measured activity of these two promoter regions by
treating cells with estrogen 24 hr post-transfection with estradiol
that increased the activity of both promoters at 12 and 24 hrs
(Figure 4D). Taken together, these results demonstrated that the
upstream promoter region of HOXB13 gene stimulated promoter
activity but did not contribute to estrogen responsiveness.
To identify the DNA methyltransferase (DNMT) that catalyzes
methylation of HOXB13, we measured its methylation status in
the wild type and mutant HCT cell lines lacking DNMT1,
DNMT3B or both. Massarray analysis showed that the upstream
CGI is heavily methylated in the wild type and DNMT3B2/2
cells but is significantly hypomethylated at certain CpGs in
DNMT12/2 cells and almost completely in double knock out
(DKO) cells (Figure 4E and Tables S4 and S5). These results
indicate that although DNMT1 alone can methylate certain
CpGs, its cooperation with DNMT3B is required for efficient
methylation of the upstream CGI. Notably, promoter CGI is not
methylated in any of these 4 cell lines. Surprisingly, HOXB13
expression is upregulated only in DNMT12/2 cells compared to
the wild type cells (Figure 4E). Significant downregulation of
ERa (Figure 4E), an activator of HOXB13 [45] probably
accounts for HOXB13 suppression in DNMT3B2/2 and DKO
cells. Increase in HOXB13 expression in DNMT12/2 cells
suggests that methylation at certain CpGs in the upstream CGI
suppresses HOXB13 expression. Thus, the upstream CGI
probably functions as an enhancer and its methylation partially
suppresses but does not silence HOXB13 expression.
Ectopic expression of TBX18 and HOXB13 inhibits
growth, clonogenic survival and anchorage independent
growth of colon cancer cells
We next explored the anti-tumorigenic properties of TBX18
and HOXB13 in colon cancer cells. TBX18, a member of T-box
family of transcription factor, is expressed in the segmented
somites and in the limb bud [46]. TBX18 knock out mice die
immediately after birth due to severe defects in organs deriving
from the lateral sclerotome [47]. In contrast, ubiquitously
expressed HOXB13 is a member of homeobox super family
involved in establishing cell fate during embryonic development
and maintaining differentiation state in adults [48,49]. HOXB13 is
upregulated in many solid tumors including cancers of the
endometrium, cervix, ovary and prostate whereas it is down
regulated in renal cell carcinoma, melanoma and colon cancer
[45]. To study the potential role of HOXB13 and TBX18 in
modulating tumorigenic property of colon cancer cells we
expressed these proteins using retroviral vector (pBabe) in the
nonexpressing colon cancer cell lines RKO and DLD1b. Ectopic
expression of the proteins was measured in puromycin-selected
cells by Western blot analysis with anti-Flag antibody (Figure 5A).
The growth rates of TBX18 and HOXB13 expressing versus
nonexpressing cells were assessed by MTT assay. Overexpression
of these proteins resulted in a significant decrease in the growth
rate of the cells compared to vector starting from day 1 in both cell
lines (Figure 5B), which correlated with dramatic reduction in
replication potential in RKO cells expressing TBX18 or HOXB13
compared to vector transfected cells (Figure 5C). Similarly,
clonogenic survival of RKO cells expressing these transcription
factors was significantly reduced (Figure 5D). Ectopic expression
of HOXB13 and TBX18 in another nonexpressing cell line,
DLD1b inhibited these properties (data not shown). Together,
these results demonstrated that TBX18 and HOXB13 severely
compromised tumorigenic potential of colon cancer cells in vitro.
HOXB13 but not TBX18 inhibits growth of colon cancer
cells in nude mice
We next investigated whether HOXB13 and TBX18
expression could inhibit ex vivo growth of colon cancer cells.
For this purpose, RKO cells expressing either HOXB13 or
TBX18 and vector transfected cells were injected into the flanks
of nude mice. Mice were monitored for tumor growth every week
and tumor size was measured. Tumor growth was visible as
early as one week in mice injected with the control and TBX18
expressing cells. In contrast, the tumor was not detectable in
most of the animals injected with HOXB13 expressing cells
(Figure 6A). At the end of the experiment, the mice were
sacrificed, tumors were removed and their weights and volumes
were determined. Notably, HOXB13 expressing cells could not
form tumors in majority of animals (Figure 6B, C). These cells
formed only two visible tumors in mice. Surprisingly, no
significant change in tumor gr o w t hi nR K Oc e l l se x p r e s s i n g
TBX18 was observed. Western blot analysis with anti-Flag
antibody to detect ectopic TBX18 showed that the tumors
developed nude mice expressed TBX18 (Figure 6D)s u g g e s t i n g
that lack of inhibition of tumor growth in nude mice was not
due to loss of TBX18 expression. It is likely that some host
factor(s) in the tumor microenvironment antagonizes the tumor
suppressor function of TBX18 in nude mice. Similar results
were observed in HCT116 and DLD1b cells (data no shown).
Thus, HOXB13 functions as a tumor suppressor in colon cancer
cells both in vitro and ex vivo.
Discussion
It is now well established that hypermethylation is a common
mechanism for silencing tumor suppressor genes in cancer cells.
Figure 4. Methylation of the CpGs spanning upstream and promoter regions of HOXB13 gene in primary colorectal tumors and
colon cancer cell lines by MassARRAY. A and B. Potential methylatable CpGs in these regions are shown after bisulfite conversion.
CpGs sequenced by MassARRAY are boxed and numbered. It is notable that this technique provides average methylation status of CpGs that are in
close proximity (numbered together as 1, 2 etc). Gray bars indicate samples that could not be sequenced. C.i. HEAT map of methylation profile of
CpGs located within upstream CGI and promoter (TSS) region. The same amplicon of methylation density ranging from 0 to 100% was used to
generate standard curve. C.ii. Box plot of quantitative analysis of methylation density in the upstream CGI and promoter regions in primary colorectal
tumors and normals. Significance was assessed by Welch test (adaptation of t test, parametric, unequal variance, one-tailed). D. Upstream region
(25.4 kb) activates HOXB13 promoter activity in colon cancer cells. HOXB13 promoter regions (21.2 kb and 25.4 kb) cloned into pGL3 basic
vector (RLU1) were transfected into HCT116 cells along with internal control pRLTK (RLU2), followed by treatment with 10 nM estradiol (E) in phenol
red free medium containing 5% charcoal stripped serum for different time periods. E. Only the upstream CGI is methylated in HCT cells, which
undergoes site-specific and global demethylation by DNMT1 alone and both DNMT1, DNMT3B, respectively. i) MassARRAY, ii) real-time RT-PCR
analysis of HOXB13, and iii) RT-PCR analysis of ERa and GAPDH.
doi:10.1371/journal.pone.0010338.g004
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PLoS ONE | www.plosone.org 9 April 2010 | Volume 5 | Issue 4 | e10338Figure 5. HOXB13 and TBX18 demonstrate anti-tumorignic property in colon cancer cells in vitro. A. Western blot analysis of cell
extracts prepared from RKO cells expressing Flag-tagged HOXB13 or TBX18. Analysis of cell growth by MTT assay (B), replication potential by
3H1-
thymidine incorporation (C), clonogenic survival (D) of RKO cells (pool and a clone selected at random). Each assay was performed in triplicate. Single
and double asterisks denote p values #0.05 and #0.01, respectively.
doi:10.1371/journal.pone.0010338.g005
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perceived to be an alternate strategy for cancer therapy,
considerable effort has been expended to identify novel tumor
suppressor genes in specific cancer types that are silenced by
methylation. Clinical trials of Vidaza and Dacogen against
different cancers underscore the significance of epigenetic therapy
in cancer [50,51]. Further, differentially methylated genes could
be potential biomarkers for colorectal cancer. Indeed, recent
studies have shown that some of the hypermethylated genes could
be detected in the stool of colon cancer patients [41,52].
DNA methyltransferases, expressed at relatively low levels in
somatic cells, are frequently upregulated in cancer cells. Gain of
function studies have shown that Dnmt3b but not Dnmt3a
promotes colon tumorigenesis in APC
Min/+ mice by inducing de
novo methylation of multiple genes harboring CpG islands [22].
It, therefore, becomes important to identify the targets of
DNMT3B in colon cancer cells to understand its function in
tumorigenesis. A recent study has used expression profiling to
identify its targets in colon cancer cell lines [53]. To our
knowledge, the present study is the first report on the identification
of direct DNMT3B targets in colon cancer cells using ChIP-on-
chip with antibodies that are specific for DNMT3B. The targets
identified include not only well known tumor suppressors such as
P16/INK4A, DCC, CAVEOLIN1, PGRMC1 but also novel genes like
TBX18, TBX5, SLIT1, DGKI. Activation of some of these genes
after treatment with demethylating agents confirmed that
methylation indeed silenced their expression in colon cancer cells.
DNMT1 and DNMT3B function co-operatively to methylate and
silence many tumor suppressor genes in colon cancer cells [23]. It
is, therefore, conceivable that both enzymes could act in concert to
alter methylation status of the target genes, as observed in
HOXB13 upstream CGI (Figure 4E).
An important observation is that a validated set of genes (TBX5,
DCC, DGKI, CDH26, HOXB13, CAVEOLIN1, PGRMC1, GNA11,
TBX18, ZBTB3 and DMRT1) are indeed associated with
DNMT3B and that they are methylated in more than one colon
cancer cell line relative to normal colon epithelial cells (CCD841).
Among these, only DCC [54] and CAVEOLIN1 [55] have recently
been reported to be methylated in colorectal carcinoma. DMRT1
is methylated in gastric cancer [56] whereas HOXB13 is
methylated in melanoma [57], renal cancer [58] and breast
cancer [45]. Further, analysis of a subset of these genes (DCC,
TBX18, TBX5, SLIT1) in primary colon cancer revealed tumor-
specific methylation. Recently several investigators have identified
genes methylated in colorectal cancer some of which were also
detected in the stool of colorectal cancer patients [41]. Different
etiology, genetic background and the techniques used probably
account for the identification of distinct methylated genes [59].
Cluster analysis demonstrated that tumors with dense methylation
at the upstream CGI of HOXB13 gene clustered together (Figure
S1). It would be of interest to analyze a large cohort of colorectal
tumors to determine whether methylation of HOXB13 occurs in
specific type of tumors and this epigenetic modification can be
used as a diagnostic or prognostic marker for colorectal cancer.
HOXB13 belongs to the homeobox family of transcription
factors. It is a unique developmentally regulated protein that is up-
or down-regulated depending upon the cellular context. While it is
upregulated in ovarian [60] and endometrial cancers [61] where it
functions as a tumor promoter, its expression is suppressed in
malignant melanoma [57], renal [58], prostate [62], colorectal
[63] and breast [45] cancer. HOXB13 is methylated in malignant
melanoma, renal and breast cancer in the CGIs spanning the
immediate upstream promoter and exon 1. Surprisingly, this
region is essentially methylation free in normal colon and
colorectal tumors (Figure 4). Methylation at an upstream CGI
located ,4.5 kb upstream of the HOXB13 transcription start site
in primary colorectal tumors and colon cancer cell lines suggests
that chromatin structure of this region acquires a unique
conformation accessible to DNMTs. C/EBPa is another tran-
scription factor that is tumor-specifically methylated at an upsteam
CGI in lung [64] and head and neck cancer [65]. Recent high
throughput analysis has identified many more genes that are
methylated at far upstream CGIs and even in coding regions [6].
The upstream CGI of HOXB13 appears to contribute to its
promoter activity in colon cancer cells and harbors several
conserved cis-regulatory elements some of which encompass
CpG dinucleotides. It is, therefore, likely that methylation of this
region is involved in modulating expression of HOXB13 and that
this mechanism is unique to colon cancer cells. It would be of
interest to examine whether HOXB13 knockout mice are
susceptible to colon tumorigenesis spontaneously, after crossing
with Apc/
Min+, Mlh1
2/2 mice or upon exposure to carcinogens.
Similarly, identification of HOXB13 target genes in colon
epithelial cells is likely to elucidate the mechanism of its tumor
Figure 6. HOXB13 but not TBX18 inhibited ability of RKO cells
to form tumor in nude mice. One million cells in PBS (100 ml) were
injected into the flanks of nude mice and tumor size was monitored
every week using a caliper. After 25 days tumors were excised and their
weights were documented. A. Time course of the progression of tumor
growth. B. Photograph of the tumors developed by vector-transfected,
HoxB13 or TBX18 expressing cells. C. Tumor weight at the time of
sacrifice. D. Western blot analysis of ectopic TBX-18 in the tumors T1 to
T4 (shown in A) with anti-Flag antibody.
doi:10.1371/journal.pone.0010338.g006
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antibody for HOXB13 will help us to answer this question. Studies
along these lines are in progress.
Supporting Information
Table S1 List of primers (ChIP-CHOP, COBRA, RT-PCR,
cDNA cloning and promoter regions) used in the present study.
COBRA primers were designed using Methprimer database
(http://www.urogene.org/methprimer/index1.html).
Found at: doi:10.1371/journal.pone.0010338.s001 (0.11 MB
DOC)
Table S2 Chromatin from RKO cells were immunoprecipitated
with affinity purified Dnmt3B antibodies or mock-immunoprecip-
itated. Precipitated DNA ranging in size from 0.6 to 3 kb were
subjected to CpG island microarrary. The chromatin was cleared
with pre-immune IgG and protein A beads. The precipitated
DNA was dissolved in RIPA buffer and subjected to a second
round of immunoprecipitation with the same antibody to
minimize pull down of false positive targets. This DNA was then
separated on an agarose gel and DNA from 0.5 to 3 kb in size was
purified by using Gel Extraction kit (Qiagen), labeled with Cy5-
labeled dNTP and hybridized to a CpG island library coated on
glass slides. The same amount of input DNA and mock-
immunoprecipitated DNA (with rabbit preimmune-IgG) was used
as control. We selected only those genes for further analysis where
the signal in ChIP DNA was greater than 2 fold compared to the
control rabbit IgG signal.
Found at: doi:10.1371/journal.pone.0010338.s002 (0.16 MB
DOC)
Table S3 Genomic DNA from different colon cancer and normal
colon epithelial (CCD841) cells were digested with Hpa II, Msp I or
mock-digested and an aliquot (100 ng) of DNA from each was
subjected to PCR with primers specific for CGI of each gene
followed by separation of the PCR products on an agarose gel. The
gene was codiered to be methylated if PCR product was generated
in the Hpa II digested DNA but not in Msp I digested DNA.
Found at: doi:10.1371/journal.pone.0010338.s003 (0.08 MB
DOC)
Table S4 MassARRAY data of upstream CGI of HOXB13
gene in primary colon cancer and matching colon tissues and
colon cell lines (normal and cancer). Methylation at each CpGs
was determined based on a standard curve generated using
methylation density ranging from 0% to 100% of the amplicon.
Found at: doi:10.1371/journal.pone.0010338.s004 (0.02 MB
XLS)
Table S5 MassARRAY data of promoter CGI of HOXB13
gene in primary colon cancer and matching colon tissues and
colon cell lines (normal and cancer). Methylation at each CpGs
was determined based on a standard curve generated using
methylation density ranging from 0% to 100% of the amplicon.
Found at: doi:10.1371/journal.pone.0010338.s005 (0.03 MB
XLS)
Figure S1 Unsupervised clustering of human primary colorectal
tumors (T) and matching normal colon tissues (N) methylation
based on methylation density at upstream CGI of HOXB13 as
determined by MassARRAY.
Found at: doi:10.1371/journal.pone.0010338.s006 (9.75 MB TIF)
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